ly-2452473
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2010 (NCT01160289)
Timeline
Indications
Mechanism of action
- Androgen ReceptorMODULATOR
AR modulator
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)OC(=O)N[C@H]1Cc2c(n(Cc3ccccn3)c3ccc(C#N)cc23)C1- Mol. weight
- 374.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3542265 ↗
Also known as
- ly2452473
- ly2452473
- ly2452473
- ly-2452473
- ly-2452473
- ly-2452473
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02499497 | Phase 2 | Jul 1, 2015 | Harvard University, National Institute of Nursing Research (NINR) |
| NCT01401543 | Phase 1 | Jul 1, 2011 | Eli Lilly |
| NCT01275157 | Phase 1 | Jan 1, 2011 | Eli Lilly |
| NCT01160289 | Phase 2 | Oct 1, 2010 | Eli Lilly |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 3 | 3 | 2 | 2010 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| National Institute of Nursing Research (NINR) | Government | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1